Introduction
Litigation involving infant formula and necrotizing enterocolitis (NEC) continues to expand in 2026, with hundreds of lawsuits filed across the U.S. Parents of premature infants allege that cow’s milk–based formulas increased the risk of this life-threatening condition, and that manufacturers failed to provide adequate warnings.
What Is NEC and Why It Matters
NEC is a serious gastrointestinal disease primarily affecting premature infants, causing intestinal tissue death, infection, and in severe cases, death.
Medical research has long suggested that breast milk reduces NEC risk, while formula-fed preemies may face higher vulnerability.
Core Allegations in the Lawsuits
The litigation focuses on major manufacturers, including:
- Abbott Laboratories (Similac)
- Mead Johnson (Enfamil)
Plaintiffs allege:
- Failure to warn about NEC risks
- Misrepresentation of safety for premature infants
- Aggressive hospital marketing practices
MDL Status and Case Volume
- Centralized under MDL No. 3026 (Northern District of Illinois)
- ~779 active cases as of 2026
- Coordinated pretrial proceedings with individual outcomes
At the same time, more plaintiffs are shifting to state courts, seeking faster jury trials and favorable venues.
Key 2026 Litigation Developments
- Bellwether trial (Inman v. Mead Johnson) rescheduled to July 2026
- Ongoing Chicago state court trial against Abbott (2026)
- Continued expansion of filings nationwide
Major Verdicts Driving Momentum
Recent verdicts have reshaped the litigation landscape:
- $60M verdict (Illinois – Enfamil case)
- $495M verdict (Missouri – Similac case)
- $32M settlement (California case)
These outcomes signal strong jury receptivity to failure-to-warn claims.
Scientific Debate: Causation vs. Risk Factors
A central issue remains causation:
- Plaintiffs: formula increases NEC risk in preemies
- Defense: NEC linked to absence of breast milk, not formula itself
Courts are increasingly scrutinizing expert testimony, with some rulings favoring plaintiffs’ scientific arguments.
Strategic Litigation Trends
- Shift toward state court filings
- Increased focus on hospital use of formula
- Growing pressure for global settlement discussions
What This Means for Law Firms
- High-value catastrophic injury cases
- Strong emotional narratives (infant harm/wrongful death)
- Increasing jury validation of claims
Conclusion
The NEC infant formula litigation is entering a critical phase in 2026. With major verdicts, expanding case volume, and upcoming trials, this mass tort is positioned to become one of the most closely watched product liability battles in the U.S.
Ready to grow your NEC case pipeline? Summit Edge Legal helps law firms secure qualified signed cases and scale client acquisition for complex mass tort litigation. Contact us today to see how we can support your firm.